Search hospitals > Washington > Mount Vernon

Skagit Valley Hospital Cancer Care Center

Claim this profile
Mount Vernon, Washington 98274
Global Leader in Parotid Gland Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Cervical Adenocarcinoma
Conducts research for Ovarian Cancer
88 reported clinical trials
7 medical researchers
Photo of Skagit Valley Hospital Cancer Care Center in Mount VernonPhoto of Skagit Valley Hospital Cancer Care Center in Mount VernonPhoto of Skagit Valley Hospital Cancer Care Center in Mount Vernon

Summary

Skagit Valley Hospital Cancer Care Center is a medical facility located in Mount Vernon, Washington. This center is recognized for care of Parotid Gland Cancer, Breast Cancer, Lung Cancer, Cervical Adenocarcinoma, Ovarian Cancer and other specialties. Skagit Valley Hospital Cancer Care Center is involved with conducting 88 clinical trials across 251 conditions. There are 7 research doctors associated with this hospital, such as Alison K. Conlin, Charles W. Drescher, Nitya Alluri, and Cristina P Rodriguez.

Area of expertise

1Parotid Gland Cancer
Global Leader
Skagit Valley Hospital Cancer Care Center has run 39 trials for Parotid Gland Cancer. Some of their research focus areas include:
Stage IV
Stage II
Stage III
2Breast Cancer
Global Leader
Skagit Valley Hospital Cancer Care Center has run 26 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
ER positive
PR positive

Top PIs

Clinical Trials running at Skagit Valley Hospital Cancer Care Center

Ovarian Cancer
Multiple Myeloma
Breast Cancer
Esophageal Adenocarcinoma
Lung Cancer
Esophageal Cancer
Gastric cancer
Esophageal cancer
Parotid Gland Cancer
Cervical Adenocarcinoma
Image of trial facility.

Olaparib +/- Bevacizumab

for Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.
Recruiting2 awards Phase 34 criteria
Image of trial facility.

Surgical Procedures

for Reducing Ovarian Cancer Risk

This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.
Recruiting1 award N/A

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Skagit Valley Hospital Cancer Care Center?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security